{
    "nctId": "NCT06087120",
    "briefTitle": "Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.",
    "officialTitle": "Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Female, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Determine the detection rate and change of ctDNA in blood samples of cancer patients before, during, and after neoadjuvant treatment.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female,18 years old and older,\n* Are diagnosed with stage II-III HER2+/Triple Negative breast cancer and indicated for neoadjuvant chemotherapy,\n* FFPE sample is available at the time of diagnosis and operation,\n* Are voluntary to participate in the study.\n\nExclusion Criteria:\n\n* Recurrent breast cancer,\n* Other cancer metastasis to the breast,\n* Have been or are being treated for cancer,\n* Patients did not agree to participate in the studies.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}